• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial

tetano

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2025 Jul 17;12(8):ofaf415.
doi: 10.1093/ofid/ofaf415. eCollection 2025 Aug. Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023

Asuka Nishigaki[SUP] 1 2 [/SUP], Ryo Kinoshita[SUP] 1 [/SUP], Shoko Sakuraba[SUP] 3 [/SUP], Jun Sugihara[SUP] 3 [/SUP], Tadaki Suzuki[SUP] 1 [/SUP], Motoi Suzuki[SUP] 1 [/SUP], Daisuke Yoneoka[SUP] 1 [/SUP]



Affiliations
Abstract

We compared severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody seroprevalence using 3 types of residual blood samples simultaneously collected in November-December 2023 from blood donors, commercial laboratories, and health checkups. Overall seroprevalence ranged from 53.5% to 58.8%, and notable variations were observed among the 30-39 and 50-59 age groups, highlighting the importance of multisource seroepidemiological surveillance.

Keywords: COVID-19; SARS-CoV-2; seroepidemiology; seroprevalence; surveillance.

​
 
You must log in or register to reply here.
Back
Top Bottom